Dr Richard Perry is a Consultant Neurologist at Imperial Healthcare with over 10 years experience. He has special interest in memory disorders, dementias, cognitive disorders, old age psychiatry and medicine for the elderly.
His clinics specialise in seeing younger, and more complex patients and he receives referrals from all over the UK. In December 2013, he was the first UK clinician to use amyloid PET imaging as a technique in Alzheimer’s Disease diagnosis.
Dr Perry completed his medical degree at the medical college of St Bartholomew’s Hospital in 1990. His specialist experience in memory disorders and dementia was gained in Cambridge from 1995 to 1999 and in San Francisco from 1999 to 2000.
Since 2005, Dr Perry has developed a facility within Imperial to run clinical trials of new disease modifying agents in early or prodromal Alzheimer’s Disease. Investigator led studies examining links between depression and Alzheimer’s and are currently testing smart phone apps to aid in detection of early cognitive impairment.
Dr Perry undertakes medicolegal work via Re:Cognition Health.
Dr Perry undertakes lecturing and advisory work, he was an invited speaker at the International Dementia Conference in Kumamoto, the European Nuclear Medicine Society in Hamburg, as well as at several UK institutions. He sits on advisory boards for drug development in Alzheimer’s for Lilly, Roche, and Merck. He is also a grants reviewer and advisor for the Alzheimer’s Society and Alzheimer’s Research UK.